Axovant Sciences Announces Public Offering of Common Shares
December 13 2018 - 4:56PM
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it
has commenced an underwritten public offering of its common shares.
All of the common shares are being offered by Axovant. In
connection with this offering, Axovant expects to grant the
underwriters a 30-day option to purchase additional common
shares in the offering on the same terms and conditions.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the offering. The offering is subject to
market conditions, and there can be no assurance as to whether or
when the offering may be completed, or the actual size or terms of
the offering.
A shelf registration statement relating to the offered common
shares was filed with the Securities and Exchange Commission (SEC),
and was declared effective on January 13, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
SEC's website, located at www.sec.gov. Before you
invest, you should read the preliminary prospectus supplement and
accompanying prospectus together with other documents that Axovant
has filed with the SEC for more complete information about Axovant
and the offering. Copies of the preliminary prospectus supplement
and accompanying base prospectus related to the offering may be
obtained, when available, from Jefferies, LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at
Prospectus_Department@Jefferies.com; and Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
New York, NY 10017, or by telephone at (212) 518-9658, or by email
at GSEquityProspectusDelivery@guggenheimpartners.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant Axovant is a clinical-stage
gene therapy company focused on developing a pipeline of innovative
product candidates for debilitating neurological diseases such as
Parkinson's disease, GM1 gangliosidosis, Tay-Sachs and Sandhoff
diseases, oculopharyngeal muscular dystrophy (OPMD), amyotrophic
lateral sclerosis (ALS), frontotemporal dementia, and other
indications.
SOURCE Axovant Sciences
Contacts:
Investors
Tricia Truehart(631) 892-7014investors@axovant.com
Media
Lara Yuan(646) 802-3585media@axovant.com
Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From Apr 2023 to Apr 2024